Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

BMY

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Sunday, June 4, 2017, at 6:30 p.m. EDT (5:30 p.m. CDT) to discuss company strategy and review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of company strategy and data presented at the meeting, with a focus on the company’s immuno-oncology portfolio, and address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at investor.bms.com, by dialing toll free (800) 236-0877 or international (719) 457-1036, confirmation code: 3209540. Materials related to the call will be available at the same website prior to the call. A replay of the call will be available beginning at 10:00 p.m. EDT on June 4 through 10:00 p.m. EDT on June 18. The replay can be accessed at investor.bms.com or by dialing (888) 203-1112 or (719) 457-0820, confirmation code: 3209540.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitter, YouTube and Facebook.

Bristol-Myers Squibb
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today